Evidence map›Paper›PMID 41599091›Full record

ArticlePathogens (Basel, Switzerland)2026

Comparison of Effectiveness Between Cysticidal and Surgical Treatments in Patients with Intraventricular Neurocysticercosis: A Single-Center Experience.

Alex Aarón Agallo-Martínez, Rebeca Ramírez-Bustamante, Polet Juárez-Ortíz, Ximena Gutiérrez-Bonilla, Sergio Moreno Jiménez, Roger Carrillo-Mezo, Agnès Fleury

Abstract readComparative Study
In one paragraph

Article in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alex Aarón Agallo-MartínezUnidad de Neuroinflamación, Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigación Biomédicas, Universidad Nacional Autónoma de México, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez (INNN-MVS), México City 14269, Mexico.ORCID 0009-0008-0581-3517
Rebeca Ramírez-BustamanteUnidad de Neuroinflamación, Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigación Biomédicas, Universidad Nacional Autónoma de México, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez (INNN-MVS), México City 14269, Mexico.
Polet Juárez-OrtízUnidad de Neuroinflamación, Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigación Biomédicas, Universidad Nacional Autónoma de México, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez (INNN-MVS), México City 14269, Mexico.ORCID 0009-0009-9700-0739
Ximena Gutiérrez-BonillaUnidad de Neuroinflamación, Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigación Biomédicas, Universidad Nacional Autónoma de México, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez (INNN-MVS), México City 14269, Mexico.
Sergio Moreno JiménezDepartamento de Neurocirugía, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, México City 14269, Mexico.ORCID 0000-0001-9932-0917
Roger Carrillo-MezoDepartamento de Neuroimagen, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, México City 14269, Mexico.ORCID 0000-0001-8719-4589
Agnès FleuryUnidad de Neuroinflamación, Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigación Biomédicas, Universidad Nacional Autónoma de México, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez (INNN-MVS), México City 14269, Mexico.ORCID 0000-0002-8930-2202

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurocysticercosis (NCC) remains a major public health problem in endemic countries. Clinical manifestations and therapeutic strategies vary depending on the location of the parasite. While the benefits of cysticidal treatment are well established for parenchymal and subarachnoid NCC, the optimal management of intraventricular NCC (IVNCC) remains controversial. We conducted a retrospective study of 51 patients: 37 (72.54%) received cysticidal treatment as initial therapy and 14 (27.45%) underwent neurosurgical intervention. Although six months after treatment, the proportion of patients with inactive disease was higher in the surgical group, no significant difference was observed after one year. Patients in both groups showed significant improvement in functionality as measured by the Karnofsky Index (KI), with no significant difference between groups. These results are consistent with cysticidal treatment being a valid therapeutic option for IVNCC, with the choice of management largely determined by the available medical infrastructure and the degree of specialization of healthcare personnel.

Indexed as

NeurocysticercosisAdolescentAdultAnimalsCerebral VentriclesFemaleHumansMaleMiddle AgedNeurosurgical ProceduresRetrospective StudiesTreatment OutcomeYoung Adultcysticidal treatmentfunctionalityMexiconeurocysticercosisneuroendoscopyT. soliumventricle

Identifiers

PMID41599091
PMCPMC12844849

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.